Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Therapy
Studies from Sun Yat-Sen University, Cancer Center in the area of acute myeloid leukemia therapy published
April 13th, 2008
Researchers detail in 'Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia,' new data in acute myeloid leukemia. "Previously, we and others showed that mitotic Aurora-A kinase (Aur-A) was required for accurate mitotic entry and proper spindle assembly. In this study, we found that expression of Aur-A was markedly elevated in bone marrow mononuclear cells (BMMCs) obtained from a significant portion of de novo acute myeloid leukemia (AML) patients," scientists in Guangzhou, People's Republic of China report. "Targeting human primary AML cells with Aur-A kinase inhibitory VX-680 led to apoptotic cell death...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
